Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 3181 AL 3195

Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders

Jellinger KA.

J Neural Transm (Vienna). 2019 Aug;126(8):997-1027. doi: 10.1007/s00702-019-02030-y. Epub 2019 Jun 24.

Nanostructure Endows Neurotherapeutic Potential in Optogenetics: Current Development and Future Prospects

Sardoiwala MN, Srivastava AK, Karmakar S, Roy Choudhury S.

ACS Chem Neurosci. 2019 Aug 21;10(8):3375-3385. doi: 10.1021/acschemneuro.9b00246. Epub 2019 Jun 19.

Do Disruptions in the Circadian Timing System Contribute to Autonomic Dysfunction in Huntington's Disease?

Park S, Colwell CS.

Yale J Biol Med. 2019 Jun 27;92(2):291-303. eCollection 2019 Jun.

Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers

Li F, Li K, Li C, Luo S; PREDICT-HD and ENROLL-HD Investigators of the Huntington Study Group.

J Huntingtons Dis. 2019;8(3):323-332. doi: 10.3233/JHD-190345.

Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson's Disease, Atypical Parkinsonisms, and Other Movement Disorders

Peralta C, Biafore F, Depetris TS, Bastianello M.

Curr Neurol Neurosci Rep. 2019 Jun 29;19(8):56. doi: 10.1007/s11910-019-0966-3.

Microorganisms, Tryptophan Metabolism, and Kynurenine Pathway: A Complex Interconnected Loop Influencing Human Health Status

Dehhaghi M, Kazemi Shariat Panahi H, Guillemin GJ.

Int J Tryptophan Res. 2019 Jun 19;12:1178646919852996. doi: 10.1177/1178646919852996. eCollection 2019.

Antisense therapies for movement disorders

Scoles DR, Pulst SM.

Mov Disord. 2019 Aug;34(8):1112-1119. doi: 10.1002/mds.27782. Epub 2019 Jul 8.

Antisense Oligonucleotide Therapies for Neurodegenerative Diseases

Bennett CF, Krainer AR, Cleveland DW.

Annu Rev Neurosci. 2019 Jul 8;42:385-406. doi: 10.1146/annurev-neuro-070918-050501.

Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate

Weber JJ, Clemensson LE, Schiöth HB, Nguyen HP.

Biochem Pharmacol. 2019 Oct;168:305-318. doi: 10.1016/j.bcp.2019.07.002. Epub 2019 Jul 5.

Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling

Wu Y, Chen M, Jiang J.

Mitochondrion. 2019 Nov;49:35-45. doi: 10.1016/j.mito.2019.07.003. Epub 2019 Jul 6.

Manganese-Induced Neurotoxicity: New Insights Into the Triad of Protein Misfolding, Mitochondrial Impairment, and Neuroinflammation

Harischandra DS, Ghaisas S, Zenitsky G, Jin H, Kanthasamy A, Anantharam V, Kanthasamy AG.

Front Neurosci. 2019 Jun 26;13:654. doi: 10.3389/fnins.2019.00654. eCollection 2019.

Imaging Mass Spectrometry: A New Tool to Assess Molecular Underpinnings of Neurodegeneration

Chen K, Baluya D, Tosun M, Li F, Maletic-Savatic M.

Metabolites. 2019 Jul 10;9(7):135. doi: 10.3390/metabo9070135.

Quality Control in Huntington's Disease: a Therapeutic Target

Rai SN, Singh BK, Rathore AS, Zahra W, Keswani C, Birla H, Singh SS, Dilnashin H, Singh SP.

Neurotox Res. 2019 Oct;36(3):612-626. doi: 10.1007/s12640-019-00087-x. Epub 2019 Jul 11.

The role of water in amyloid aggregation kinetics

Stephens AD, Kaminski Schierle GS.

Curr Opin Struct Biol. 2019 Oct;58:115-123. doi: 10.1016/j.sbi.2019.06.001. Epub 2019 Jul 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias